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Abstract
Derangements in calcium cycling have been described in failing hearts, and preclinical studies have suggested
that therapies aimed at correcting this defect can lead to improvements in cardiac function and survival. One
strategy to improve calcium cycling would be to inhibit phospholamban (PLB), the negative regulator of
SERCA2a that is upregulated in failing hearts. The goal of this study was to evaluate the safety and efficacy of
using adeno-associated virus (AAV)-mediated cardiac gene transfer of short hairpin RNA (shRNA) to knock
down expression of PLB. Six dogs were treated with self-complementary AAV serotype 6 (scAAV6)
expressing shRNA against PLB. Three control dogs were treated with empty AAV6 capsid, and two control
dogs were treated with scAAV6 expressing dominant negative PLB. Vector was delivered via a percutaneously
inserted cardiac injection catheter. PLB mRNA and protein expression were analyzed in three of six shRNA
dogs between days 16 and 26. The other three shRNA dogs and five control dogs were monitored long-term
to assess cardiac safety. PLB mRNA was reduced 16-fold, and PLB protein was reduced 5-fold, with treatment.
Serum troponin elevation and depressed cardiac function were observed in the shRNA group only at 4 weeks.
An enzyme-linked immunospot assay failed to detect any T cells reactive to AAV6 capsid in peripheral blood
mononuclear cells, heart, or spleen. Microarray analysis revealed alterations in cardiac expression of several
microRNAs with shRNA treatment. AAV6-mediated cardiac gene transfer of shRNA effectively knocks down
PLB expression but is associated with severe cardiac toxicity. Toxicity may result from dysregulation of
endogenous microRNA pathways.
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Abstract
Derangements in calcium cycling have been described in failing hearts, and preclinical studies have suggested
that therapies aimed at correcting this defect can lead to improvements in cardiac function and survival. One
strategy to improve calcium cycling would be to inhibit phospholamban (PLB), the negative regulator of
SERCA2a that is upregulated in failing hearts. The goal of this study was to evaluate the safety and efficacy of
using adeno-associated virus (AAV)-mediated cardiac gene transfer of short hairpin RNA (shRNA) to knock
down expression of PLB. Six dogs were treated with self-complementary AAV serotype 6 (scAAV6) expressing
shRNA against PLB. Three control dogs were treated with empty AAV6 capsid, and two control dogs were
treated with scAAV6 expressing dominant negative PLB. Vector was delivered via a percutaneously inserted
cardiac injection catheter. PLB mRNA and protein expression were analyzed in three of six shRNA dogs between
days 16 and 26. The other three shRNA dogs and five control dogs were monitored long-term to assess cardiac
safety. PLB mRNA was reduced 16-fold, and PLB protein was reduced 5-fold, with treatment. Serum troponin
elevation and depressed cardiac function were observed in the shRNA group only at 4 weeks. An enzyme-linked
immunospot assay failed to detect any T cells reactive to AAV6 capsid in peripheral blood mononuclear cells,
heart, or spleen. Microarray analysis revealed alterations in cardiac expression of several microRNAs with
shRNA treatment. AAV6-mediated cardiac gene transfer of shRNA effectively knocks down PLB expression but
is associated with severe cardiac toxicity. Toxicity may result from dysregulation of endogenous microRNA
pathways.
Introduction
Heart failure (HF) is a major cause of morbidity andmortality, and transplantation is the only definitive cure
for end-stage disease. Because the demand for donor organs is
much higher than the supply, novel therapies are needed to
augment current treatment modalities. It has been reported
that defects in calcium handling secondary to dysregulation of
the sarcoplasmic reticulum-associated proteins sarcoplasmic
reticulum calcium ATPase 2a (SERCA2a) and phospholamban
(PLB) are present in the failing hearts of humans and animals
(Kaye et al., 2008; Vinge et al., 2008). Therefore, targeting these
proteins in the failing heart may be a novel therapeutic option.
Indeed, adeno-associated virus (AAV)-mediated over-
expression of SERCA2a has been successfully used to restore
mechanical and energetic function in failing rat hearts (Sakata
et al., 2007) and to reverse cardiac dysfunction in a porcine
model of HF (Kawase et al., 2008), and a clinical trial of
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AAV-mediated overexpression of SERCA2a in patients with
New York Heart Association stage III/IV HF is in progress
(Hajjar et al., 2008; Jaski et al., 2009). Other investigators have
used virus-mediated expression of a dominant negative PLB
(dnPLB) mutant to suppress HF progression in both small and
large animal models of ischemic and nonischemic cardiomy-
opathy (Hoshijima et al., 2002; Iwanaga et al., 2004; Kaye et al.,
2007). No clinical trials using dnPLB have been initiated yet.
Another strategy to inhibit PLB would be to employ AAV-
mediated cardiac delivery of short hairpin RNA (shRNA) di-
rected against PLB. Studies using virus-mediated transfer of
shRNA directed against PLB in cardiomyocyte culture have
demonstrated that it is an effective method for both knocking
down PLB expression and modulating calcium handling
(Fechner et al., 2007; Andino et al., 2008), and one study in a rat
model of HF demonstrated that AAV-mediated transfer of
shRNA is effective in restoring cardiac function and geometry
(Suckau et al., 2009). In addition, because the gene product in
this case would be a functional RNA and not a mutant protein
(dnPLB), this strategy would avoid the potential of evoking a T
cell response directed against cells expressing the transgene, as
has been reported after AAV-mediated cardiac gene transfer
of a modified, soluble TNF receptor in baboons (McTiernan
et al., 2007). This is an important consideration when consid-
ering large animal and clinical trials.
Therefore, in this preclinical study, our goal was to assess
the safety and efficacy of using self-complementary AAV6
(scAAV6)-mediated delivery of shRNA directed against PLB
in the canine heart before evaluating it in a canine model of
HF. We found that AAV-mediated expression of shRNA
directed against PLB is effective at knocking down PLB ex-
pression in the canine heart. However, our safety assessment
revealed that healthy canines treated with shRNA, but not
empty AAV6 capsid or dnPLB, experienced serum cardiac
troponin I elevation, cardiac dysfunction, and alteration of
cardiac microRNA expression, suggesting that this approach
may not be a feasible therapeutic strategy.
Materials and Methods
Vector design and production
Self-complementary AAV6 vectors were produced ac-
cording to the previously described pseudotyping protocol
by the Vector Core of the University of Pennsylvania (Phi-
ladelphia, PA) (Gao et al., 2002). Briefly, recombinant AAV
genomes containing AAV2 inverted terminal repeats (ITRs)
were packaged by triple transfection of 293 cells with a cis
plasmid carrying the enhanced green fluorescent protein
(EGFP) transgene, an adenovirus helper plasmid, and a
chimeric trans plasmid carrying the AAV2 rep gene fused to
the capsid gene of AAV6. Self-complementary vectors con-
tained a mutation in the termination sequence of the 5¢ ITR to
allow synthesis and encapsidation of a dimeric inverted re-
peat of the transgene cassette (McCarty et al., 2001). The
empty capsid used in this study was AAV6 capsid devoid of
ITR-containing DNA. It was purified through a CsCl step
gradient as described in detail previously (Grimm et al., 2003)
and was quantified by silver stain analysis.
The scAAV6-dnPLB construct was designed to express canine
PLB with an S16E mutation under the control of the constitutive
chicken b-actin promoter with cytomegalovirus enhancer (CB)
(Kaye et al., 2007). The scAAV6-shRNA-PLB construct was de-
signed to express shRNA directed against canine PLB under the
control of the U6 promoter (Suckau et al., 2009).
Animal use and vector delivery protocol
All animals were handled in compliance with National
Institutes of Health (Bethesda, MD) and institutional guide-
lines that were approved by the Institutional Animal Care
and Use Committee of the University of Pennsylvania.
Eleven mongrel canines (5–10 kg, 3–6 months old) were used
in this study. They were randomized to receive either
scAAV6-U6-shRNA-PLB (n = 6), scAAV6-CB-dnPLB (n = 2), or
AAV6 capsid only (n = 3) at a dose of 5 · 1011 genome copies/kg.
The vector delivery procedure was performed under
general anesthesia, and dogs were placed in left lateral re-
cumbency. Heart rate, respiratory rate, systolic blood pres-
sure, electrocardiogram, and oxygen saturation were
monitored throughout the anesthetic period. A right carotid
arteriotomy was performed, and a 7-French introducer was
placed in the vessel, followed by insertion of the injection
catheter. This catheter was a steerable injection catheter with
an adjustable-length core needle (MyoCath; Bioheart, Sun-
rise, FL), which has previously been employed to deliver
AAV vector in our laboratory (Bish et al., 2008, 2010). The
catheter was flushed with heparinized blood before vector
infusion to prevent inactivation of the virus (Marshall et al.,
2000). Next, under fluoroscopic guidance, the catheter was
advanced into the left ventricular cavity, and by steering the
needle tip and adjusting the needle length, approximately 60
transendocardial injections of 250 ll each were performed to
target the left ventricular free wall and interventricular sep-
tum from base to apex and from endocardium to epicardium
with AAV vector. Contrast medium was added to the vector
solution so that injection sites could be visualized. This al-
lowed us to differentiate between injected and uninjected re-
gions of the heart and helped to ensure that the vector solution
was distributed globally throughout the myocardium.
For each procedure vector was mixed with 2 mL of sterile
contrast solution (Omnipaque; GE Healthcare, Piscataway,
NJ) and diluted with sterile saline to produce 15 mL for in-
jection. Lidocaine (2 mg/kg as a bolus followed by a constant
rate infusion at 50 lg/kg/min) was initiated if ventricular
tachycardia developed during the procedure. After recovery,
dogs were treated with carprofen for 2 days and with
amoxicillin–clavulanic acid for 5 days.
Echocardiography
Echocardiography was performed with a Sonos 7500
(Philips Healthcare, Bothell, WA) with standard two-
dimensional, M-mode, and Doppler capability (color and
spectral imaging at each time point). Evaluation was per-
formed with the animal in right and left lateral recumbency
by using a cut-out table and imaging from below. The same
sonographer performed all assessments (M.M.S.).
Serum cardiac troponin I quantification
Serum cardiac troponin I (cTnI) was assessed with a
Stratus analyzer (Dade-Behring, Newark, DE). This analyzer
uses a two-site sandwich immunoassay to detect free and
complexed cTnI. Canine normal ranges have previously been
established (Sleeper et al., 2001).
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RT-PCR analysis
Total RNA was isolated from cardiac samples snap-frozen
in liquid nitrogen (TRIzol; Invitrogen, Carlsbad, CA) and
further purified with RNeasy columns (Qiagen, Valencia, CA)
as previously described (Evans et al., 2008). Two hundred and
fifty nanograms of total RNA from each sample were sub-
jected to single-strand reverse transcription (Applied Biosys-
tems, Foster City, CA). The resultant cDNA was used for
quantitative RT-PCR (qRT-PCR) with oligonucleotides spe-
cific for canine PLB and glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) control, using the LightCycler system
and reagents (LightCycler FastStart DNA MasterPLUS SYBR
Green I; Roche Applied Science, Indianapolis, IN). Expression
levels were assessed by calculating the crossing point (Cp),
where measured fluorescence rises above background, as the
second derivative maximum of the reaction curve. Each sample
was analyzed in duplicate and the resulting data were aver-
aged. The relative change in expression between groups was
based on the assumption that a difference of 1 Cp results from a
2-fold change in expression. Melting point analysis of experi-
mental samples confirmed that all primers were specific for
their respective transcripts, when there was only one melting
point observed for each primer pair. Controls included RNA
not subjected to reverse transcription, and water only. Primer
sequences were as follows:
Canine PLB Forward: atggataaagtccaatacctca
Canine PLB Reverse: tcagagaagcatcacaatgat
Canine GAPDH Forward: atggtgaaggtcggagtcaacggat
Canine GAPDH Reverse: gaagatggagatggacttcccgttg
Western blot analysis
Cardiac biopsies obtained for Western blotting were snap-
frozen in liquid nitrogen. Specimens were pulverized, ho-
mogenized in 10 vol of triple-detergent lysis buffer (50 mM
Tris [pH 8.0], 0.1% sodium dodecyl sulfate [SDS], 1.0% Triton
X-100, 0.5% deoxycholate [DOC], 5 mM EDTA, 50 mM di-
thiothreitol [DTT], Complete protease inhibitor [0.4 tablet/10
ml; Roche, Indianapolis, IN]), and centrifuged at 13,000 rpm
for 5 min. The protein concentration of the supernatant was
then determined by the Bio-Rad protein assay (Bio-Rad,
Hercules, CA). Fifty micrograms of each sample were elec-
trophoresed on a 4–20% SDS–polyacrylamide gel (Lonza,
Rockland, ME) after the addition of 2 · sample loading buffer
(130 mM Tris [pH 8.0], 20% glycerol, 4.6% SDS, 2% DTT,
0.02% bromophenol blue) and 5 min of denaturation at
100C. Proteins were then transferred to Immobilon-P (Mil-
lipore, Bedford, MA), using the iBlot transfer apparatus
(Invitrogen). The membrane was subsequently blocked with
5% nonfat dry milk in Tris-buffered saline containing 0.05%
Tween 20. Immunoblotting was performed to detect phos-
pholamban (1:500 dilution; Millipore) and actin (1:2000 di-
lution; Sigma-Aldrich, St. Louis, MO) as a loading control.
Detection was performed with a SuperSignal West Pico
chemiluminescent substrate kit (Pierce Protein Research
Products, Rockford, IL).
Enzyme-linked immunospot assay for T cell responses
Peripheral blood mononuclear cells (PBMCs) were iso-
lated as per standard protocol and cryopreserved until as-
sayed as previously described (Bish et al., 2008). Briefly,
tissues were obtained fresh and homogenized; red blood
cells were lysed; lymphocytes were then collected and
cryopreserved until assayed. For the enzyme-linked im-
munospot (ELISpot) assay, a peptide library consisting of
15-mers overlapping by 10 amino acids with the adjacent
peptide was synthesized for the capsid sequence of the AAV6
VP1 protein (736 amino acids, 146 peptides; Mimotopes,
Clayton, Victoria, Australia). Peptides were resuspended in
50% acetonitrile–0.1% acetic acid at a concentration of 5 mg/
ml. Peptides were arranged into a 24-pool matrix, with each
pool consisting of 12 or 13 peptides and each peptide con-
tained in 2 orthogonal pools. To test for T cell responses,
2 · 105 cells were incubated for either 24 hr (interferon-c) or
48 hr (interleukin-10) at 37C, 10% CO2, in the presence of
AAV6 peptide pools (individual peptide final concentration,
10 lg/ml) or AAV6 empty capsid (10 lg/ml; Research Vector
Core, Children’s Hospital of Philadelphia, Philadelphia, PA).
Phorbol 12-myristate 13-acetate (PMA, 50 ng/ml; Sigma-Al-
drich) and ionomycin (1 lg/ml; Sigma-Aldrich) were used as
positive controls. Medium alone (DMEM; Gibco/Invitrogen)
served as a negative control. All assays were performed in
triplicate. Canine interferon-c and interleukin-10 were assayed
with canine development module kits (R&D Systems, Min-
neapolis, MN). Assays were scored with an immunospot
reader (CTL, Cleveland, OH), and positive T cell responses
were scored as 3-fold above medium control. Results are
displayed as spot-forming units/106 cells.
MicroRNA microarray analysis
Myocardial biopsies were collected from dogs treated with
scAAV6-U6-PLB-shRNA 16–26 days previously (n = 3) and
from untreated, age-matched controls (n = 3) and snap-frozen
in liquid nitrogen. Two biopsies were collected per animal.
MicroRNA (miRNA) was extracted with an miRNA Easy
mini kit (Qiagen). miRNA expression was analyzed with
miRCURY LNA version 9.2 (Exiqon, Woburn, MA). GenePix
(GPR) files were imported into Partek Genomics Suite ver-
sion 6.4 (Partek, St. Louis, MO), where foreground median
minus background median were extracted for each channel
on each array. Data were transformed such that any ex-
tracted intensity that was less than 1 was assigned a value of
1. Data were then LOESS (locally weighted scatterplot
smoothing) normalized using log2 ratios for treated dogs
over control dogs for each array. Dye-swap pairs were av-
eraged, yielding three biological replicates for treated over
control. Statistical analysis for significantly dysregulated
miRNAs was conducted for those probes, which had log2
ratios for at least two of the three pairs.
Statistical analysis
Mean values from each experimental group were com-
pared by two-tailed Student t test. Analysis of microarray
data is described in the previous section.
Results
Study design
shRNA-mediated knockdown of cardiac PLB expression
has potential as a novel therapeutic approach in the treat-
ment of HF. Before evaluating the long-term therapeutic
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potential of this approach in a canine model of HF, we chose
to assess the safety of shRNA-mediated knockdown of PLB in
healthy canines. Six dogs were treated with scAAV6-U6-
shRNA-PLB. Three control dogs were treated with AAV6
empty capsid to establish a virus control group. An additional
two canines were treated with scAAV6-CB-PLB-S16E (dnPLB)
(Kaye et al., 2007) to establish a control group for PLB inhibi-
tion. PLB mRNA and protein levels as well as microRNA ex-
pression were analyzed between days 16 and 26 in three of the
dogs treated with PLB shRNA. The remaining dogs (three
treated with PLB shRNA, three control dogs treated with
AAV6 capsid only, and two dogs treated with dnPLB) were
monitored long term with monitoring of serum cardiac tro-
ponin I (cTnI) and cardiac function to assess the safety of AAV-
mediated PLB knockdown with shRNA.
PLB knockdown
The spatial distribution of cardiac gene transfer after in-
jection via the percutaneously inserted catheter described in
Materials and Methods has been previously published (Bish
et al., 2008, 2010). RT-PCR results revealed that PLB mRNA
expression was reduced approximately 16-fold (Fig. 1A), and
Western blot results revealed that PLB protein was reduced
approximately 5-fold (Fig. 1B) after treatment with scAAV6-
U6-shRNA-PLB. Thus, AAV-mediated cardiac delivery of
shRNA directed against PLB is effective at knocking down
cardiac PLB expression in the canine.
Long-term cardiac safety assessment
We next monitored the three remaining dogs treated with
PLB shRNA long-term to assess the safety of this procedure.
The three dogs treated with AAV6 capsid only and two dogs
treated with dnPLB were monitored as controls. Serum car-
diac troponin I elevations were noted in three of three dogs
treated with PLB shRNA, zero of three dogs treated with
AAV6 capsid only, and zero of two dogs treated with dnPLB.
The elevation was apparent by 2 to 3 weeks postinjection, with
a peak at 4–5 weeks to approximately 100-fold baseline levels
(Fig. 2A). This was associated with a decrease in fractional
shortening as measured via echocardiography (Fig. 2B). At
this time, one of three dogs treated with shRNA was killed,
and tissue was collected for analysis as detailed below. In the
remaining two of three dogs treated with shRNA, serum cTnI
levels and fractional shortening gradually improved over the
next 6–8 weeks. No abnormalities were observed in any of the
three dogs treated with AAV6 capsid only with one of three
monitored for 6 months and two of three monitored for 2 years,
or in either of the dogs treated with dnPLB, both of which were
monitored for greater than 18 months. Expression of the
dnPLB construct was confirmed both in canines before its use
in this study and in one of the long-term dnPLB canines used in
this study at 19 months (see Supplementary Fig. S1; supple-
mentary data are available online at www.liebertonline.com/
hum). The remaining dnPLB canine used in this study con-
tinues to be monitored for long-term safety assessment and is
now over 2 years posttreatment.
ELISpot assay
Next, we sought to determine the etiology of the cardiac
toxicity observed after treatment with scAAV6-U6-shRNA-
PLB. Because no toxicity was observed in any of the canines
treated with either AAV6 capsid only or scAAV6-dnPLB, it
seemed unlikely that it was secondary to a T cell response
directed against AAV6 capsid. However, because a capsid-
directed T cell response was observed in a human trial of
AAV-mediated hepatic gene transfer (Manno et al., 2006) and
a canine study of AAV-mediated skeletal muscle gene
transfer (Wang et al., 2007) at a similar time frame postin-
jection, we screened peripheral blood mononuclear cells
(PBMCs) from dogs experiencing toxicity via ELISpot for T
cells reactive to AAV6 capsid. No T cells reactive to AAV6
capsid were identified in the PBMCs isolated from these
dogs at 4 and 7 weeks postinjection, or from dogs treated
with AAV6 capsid only (Fig. 3A and B and data not shown).
In addition, no T cells reactive to AAV6 capsid were iden-
tified in the heart or spleen of the shRNA-treated dog that
was killed (Fig. 3C, D).
FIG. 1. Analysis of phospholamban (PLB) mRNA and
protein levels reveals efficacy of scAAV6-U6-shRNA-PLB in
knocking down PLB expression. (A) Quantitative RT-PCR
analysis demonstrates approximately 16-fold decreased PLB
mRNA with short hairpin RNA (shRNA) overexpression
compared with control. (B) Western blot demonstrates ap-
proximately 5-fold decreased PLB protein with shRNA
overexpression compared with control. *p < 0.05, n = 3 per
group. Tissue was collected 16–26 days postinjection. Color
images available online at www.liebertonline.com/hum
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MicroRNA microarray
Because a T cell response directed against AAV6 capsid
was not responsible for the cardiac toxicity and because PLB
inhibition via dnPLB did not induce toxicity in this study, we
continued to investigate its etiology. It was reported that
oversaturation of endogenous microRNA pathways after
AAV-mediated shRNA overexpression in mouse liver was
responsible for hepatotoxicity and death (Grimm et al., 2006).
Therefore, we next analyzed cardiac microRNA expression
by means of microarray technology. We found that cardiac
miRNA-124 expression was decreased approximately 2-fold,
and miRNA-302d expression was increased approximately
3-fold, after treatment with scAAV6-U6-shRNA-PLB (Fig. 4).
No significant changes in expression were noted for the
following microRNAs with previously reported roles in
cardiovascular physiology and pathophysiology: miRNA-1
(Yang et al., 2007; Zhao et al., 2007), miRNA-21 (Yin et al.,
2008), miRNA-133 (Care et al., 2007), miRNA-195 (van Rooij
et al., 2006), miRNA-199a (Rane et al., 2009), miRNA-208a
(van Rooij et al., 2007; Callis et al., 2009), miRNA-320 (Ren
et al., 2009) (Fig. 4).
Discussion
In this study, we demonstrated that percutaneous delivery
of scAAV6-U6-shRNA-PLB is effective at knocking down
expression of PLB in the canine heart. Our study was the first
to assess the efficacy of AAV-mediated transfer of shRNA
directed against PLB in a large animal model. A previous
report described the effective use of scAAV9-U6-shRNA-PLB
to knock down expression of PLB in a rat model of HF in-
duced by transaortic banding (Suckau et al., 2009). In this
model, decreased PLB expression was associated with res-
toration of cardiac function and geometry over a 3-month
period without any adverse effects. We designed our vector
and shRNA sequence on the basis of this report and on an-
other in the literature describing virus-mediated transfer of
shRNA directed against PLB in rat neonatal cardiomyocyte
culture, with some modifications for use in a canine model
(Fechner et al., 2007). Namely, our shRNA sequence was
directed against the same region of PLB as previously de-
scribed in the rat but modified to be canine specific. In ad-
dition, we used scAAV6 instead of scAAV9 because it has
been previously reported that scAAV6 is superior to scAAV9
in the canine heart (Bish et al., 2008).
After demonstrating the efficacy of this approach, we next
assessed its long-term safety in healthy canines as a final step
before the design of a preclinical study in a canine model of
HF. Surprisingly, we found that treatment with AAV-
shRNA-PLB was associated with elevation of serum cTnI,
with a peak at 4 to 5 weeks postinjection, and depressed
cardiac function. Cardiac function gradually improved with
normalization of serum cTnI levels by approximately 3
months postinjection. After observing this severe toxicity, we
directed our attention toward identifying its etiology.
The canines that experienced toxicity were treated with
AAV6 expressing shRNA directed against PLB; therefore, the
toxicity could have been induced by the AAV6 vector, by
inhibiting PLB, or by the shRNA itself. Because the gene
product in this case was a functional RNA and not a protein,
we did not need to consider a T cell response directed against
the expressed transgene as the etiology, as has been previ-
ously reported (McTiernan et al., 2007). However, a T cell
response directed against the AAV capsid could still be re-
sponsible for the observed toxicity. Indeed, robust cellular
immune responses directed against AAV capsid have been
described approximately 4 weeks postinjection in human li-
ver (Manno et al., 2006) and canine skeletal muscle (Wang
et al., 2007). To rule this out in our study, we performed two
separate experiments. First, we injected three dogs with
AAV6 empty capsid and monitored these animals up to 2
years. These animals did not experience elevation of serum
cTnI or depression of cardiac function, suggesting that AAV
capsid was not the cause of the toxicity. To be sure, we next
screened PBMCs, spleen, and heart from dogs that received
shRNA-PLB for T cells reactive to AAV6 capsid, using the
FIG. 2. Long-term safety assessment demonstrates cardiac
toxicity in canines treated with scAAV6-U6-shRNA- phos-
pholamban (PLB). (A) Serum cardiac troponin I (cTnI) mea-
surements were performed at baseline and up to 10 weeks
after treatment with scAAV6-shRNA-PLB (n = 3), AAV6
capsid only (n = 3), or scAAV6-dnPLB (n = 2). Serum cTnI
levels peaked at 4–5 weeks in canines treated with scAAV6-
shRNA-PLB. Because no elevation in serum cTnI was
observed in either the AAV6 capsid group or the scAAV6-
dnPLB group, both groups are represented here as Control.
(B) Cardiac function as assessed by echocardiography.
Fractional shortening (FS), a measure of cardiac contractility,
is reported for canines treated with scAAV6-shRNA-PLB vs.
control. Echocardiography was performed at multiple time
points from baseline to 11 weeks as depicted. Canines treated
with scAAV6-shRNA-PLB experienced a decline in FS be-
ginning at 4 weeks. dnPLB, dominant negative PLB.
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ELISpot assay. ELISpot is the most widely accepted and
most sensitive assay for detecting T cell responses in this
case. ELISpot was used to determine the T cell response
against AAV in a published clinical trial for hemophilia B
(Manno et al., 2006), and this same rigorous ELISpot analysis
continues to be used as the primary assay for detection of T
cell responses in current clinical and nonhuman primate
trials of AAV-mediated gene transfer for hemophilia (Min-
gozzi and High, 2011; Nathwani et al. 2011). No capsid-
reactive T cells were identified, further suggesting that AAV
capsid was not responsible for the toxicity.
Another possibility is that inhibition of PLB induced car-
diomyocyte death, as there is controversy in the literature
concerning the safety of cardiac PLB inhibition. Although
PLB knockout mice exhibit enhanced contractility without
evidence of cardiomyopathy (Slack et al., 2001), and PLB
inhibition in hamsters (Hoshijima et al., 2002) and rats
(Iwanaga et al., 2004; Sakata et al., 2007; Zhao et al., 2008;
Suckau et al., 2009) is effective in suppressing the progression
of HF, humans homozygous and heterozygous for a null
PLB L39Stop mutation develop left ventricular hypertrophy,
premature dilated cardiomyopathy, and HF (Haghighi et al.,
2003). This discrepancy in phenotype may exist because
FIG. 3. AAV6 capsid does not induce a T cell-specific response in canines treated with scAAV6-U6-shRNA-PLB. Re-
presentative ELISpot data from PBMCs obtained 4 weeks postinjection and assayed for (A) interferon-c and (B) interleukin-10
production are shown. Representative ELISpot data from lymphocytes isolated from (C) spleen and (D) heart 7 weeks
postinjection and assayed for interferon-c are shown. For all assays, cells were tested against 24 pools (5 lg/peptide, each
peptide) comprising an AAV6 capsid peptide matrix, 10 lg/ml AAV6 empty capsid, phorbol 12-myristate 13-acetate (PMA)/
ionomycin (positive control) or medium (negative control). The assay was performed in triplicate. Data are shown as spot-
forming units/106 cells. The solid line indicates 3-fold over medium background control, used to determine positive T cell
responses.
FIG. 4. Alterations in cardiac microRNA expression 16–26
days after percutaneous cardiac delivery of scAAV6-U6-
shRNA-PLB (n = 3) compared with control (n = 3). Microarray
analysis revealed significant alterations in expression of two
miRNAs after overexpression of shRNA. No significant
changes were noted in several other miRNAs with previ-
ously defined roles in the heart. *Significant, as defined by
p < 0.05 and > 1.5-fold expression change (Thum et al., 2007;
Evans et al., 2008).
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humans have a large cardiac reserve that can be regulated by
altering sarcoplasmic reticulum calcium content via PLB,
whereas small animals such as mice with resting heart rates
over 600 beats/min have relatively little cardiac reserve and
minimal ability to increase sarcoplasmic reticulum calcium
stores above their near-maximal baseline (Haghighi et al.,
2003; MacLennan and Kranias, 2003). As a result, loss of PLB
in humans, where it functions as a gatekeeper of the large
cardiac reserve, may lead to significantly increased cardiac
work and eventual cardiomyopathy and HF over years
(Haghighi et al., 2003), whereas loss of PLB in mice, where it
regulates only a minimal cardiac reserve, may lead to a rela-
tively smaller increase in cardiac work without cardiomyop-
athy over the short life span of the animal (Slack et al., 2001).
However, there is also speculation that loss of PLB in
humans may not be deleterious. Because the mutant L39Stop
PLB peptide contains the cytoplasmic domain of PLB that
interacts with and inhibits SERCA2a, it has been suggested
that PLB L39Stop is not a null mutation, but rather a con-
stitutively active inhibitor (Chien et al., 2003; Haghighi et al.,
2004). If this is the case, then L39Stop is simply another ex-
ample of a constitutively active PLB mutant responsible for
human dilated cardiomyopathy, such as the R9C (Schmitt
et al., 2003) or R14 deletion (Haghighi et al., 2006). In addi-
tion, a report describing reversal of advanced HF after de-
livery of adenovirus expressing dnPLB in a pacing-induced
porcine model provides direct evidence for the safety of PLB
inhibition in large animal hearts (Kaye et al., 2007). However,
animals in this study were monitored for only 2 weeks after
injection of dnPLB, so data describing the long-term safety of
PLB in large animal hearts are lacking. Because we wanted to
rule out PLB inhibition as a potential source of toxicity in our
dogs and because no other long-term studies of cardiac PLB
inhibition in a large animal model have been published, we
established a control group for PLB inhibition by injecting
two healthy dogs with scAAV6 expressing dnPLB. We did
not observe elevation of serum cTnI or depression in cardiac
function in these animals, which were monitored for over 18
months, confirming the safety of long-term cardiac PLB in-
hibition in a large animal.
However, it should be noted that we cannot rule out a
very late onset of cardiac dysfunction resulting from PLB
inhibition in these canines. Although PLB knockout mice
exhibit enhanced contractility (Slack et al., 2001), the effects of
inhibiting PLB in healthy hearts in a large animal model are
unknown. It may have no effect, or the effect may take more
than 2 years (the observation time in this study) to develop.
Indeed, humans with PLB mutations do not typically present
with cardiac disease until their late teens or early twenties at
the earliest (Haghighi et al., 2003).
Because we had ruled out AAV capsid and PLB inhibition
as sources of toxicity, we next investigated shRNA over-
expression as a source. A study described hepatotoxicity and
death in mice approximately 1 month after intravenous in-
jection of an AAV vector expressing various shRNA se-
quences, and it was determined that oversaturation of
endogenous microRNA pathways by the exogenous shRNA
was responsible (Grimm et al., 2006). Because the cardiac
toxicity in our study occurred at a similar time, it seemed
plausible that the same mechanism may be responsible. In-
deed, previous work has demonstrated the importance of
microRNA in the heart (Thum et al., 2008a; Small et al., 2010).
As in other tissues, microRNAs in the heart control gene
expression by binding to target mRNAs and either promot-
ing their degradation or inhibiting their translation. In doing
so, they regulate expression of genes involved in multiple
processes, such as hypertrophy (van Rooij et al., 2007), con-
duction (Callis et al., 2009), fibrosis (Thum et al., 2008b), and
apoptosis (Rane et al., 2009). In our study, we found that
treatment with shRNA was associated with alterations in
expression of miRNAs 124 and 302d. Although no definitive
roles for these miRNAs have been described in the heart,
they have been implicated in embryonic development
(Maiorano and Mallamaci, 2009; Rosa et al., 2009). In addi-
tion, dysregulation of the miRNA-302 family has been re-
ported in human HF (Thum et al., 2008a). It has been
suggested that reactivation of fetal miRNA programs may
contribute to altered gene expression in human HF (Thum
et al., 2007). Future studies in experimental animal models
are needed to define the mRNA targets and physiological
role of miRNAs 124 and 302 in the heart. In addition, future
investigation will be directed at assessing alterations in car-
diac function and in the miRNA expression profile after
treatment with additional shRNAs, including a second PLB-
specific sequence, a nonessential gene sequence, and a non-
specific/negative control sequence, to strengthen the validity
of our findings in this initial study.
In summary, we demonstrated in this study that percu-
taneous delivery of scAAV6-U6-shRNA-PLB is effective in
knocking down PLB expression in the canine heart. How-
ever, it is associated with severe cardiac toxicity that may be
secondary to oversaturation of endogenous miRNA path-
ways. Future studies using this approach should focus on
strategies to limit shRNA expression to the minimally ef-
fective dose, perhaps by designing vectors with promoters
that are weaker than the traditional polymerase III promot-
ers (H1 and U6) used to drive shRNA expression, such as
tissue-specific, polymerase II promoters (Giering et al., 2008).
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